AbbVie Wins FDA Nod for Decnupaz for Rare Blood Cancer Indication
ABBV's Decnupaz wins FDA approval for BPDCN, adding its first blood cancer ADC and a new option for an ultra-rare aggressive malignancy.
Open original sourceLoading market dashboard
ABBV's Decnupaz wins FDA approval for BPDCN, adding its first blood cancer ADC and a new option for an ultra-rare aggressive malignancy.
Open original source